Myriad Genetics MYGN Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Myriad Genetics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Myriad Genetics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Myriad Genetics's additional paid-in capital?
- Myriad Genetics (MYGN) reported additional paid-in capital of $1.49B in Q1 2026.
- How has Myriad Genetics's additional paid-in capital changed year-over-year?
- Myriad Genetics's additional paid-in capital increased by 2.1% year-over-year, from $1.46B to $1.49B.
- What is the long-term trend for Myriad Genetics's additional paid-in capital?
- Over 5 years (2020 to 2025), Myriad Genetics's additional paid-in capital has grown at a 6.1% compound annual growth rate (CAGR), from $1.11B to $1.49B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.